jueves, 30 de julio de 2020

BMC Cancer | Infection, immunity and cancer vaccines

BMC Cancer | Infection, immunity and cancer vaccines



Infection, immunity and cancer vaccines

Section edited by Christophe Nicot
This section focuses on all aspects of infectious agents associated with cancer and tumor immunology. Topics of interest include, but are not limited to, tumor immunity, immunotherapy, cancer vaccines, viral carcinogenesis and virus-host interactions.
Page 1 of 4
  1. The identification of pathologically altered neutrophil granulocyte migration patterns bears strong potential for surveillance and prognostic scoring of diseases. We recently identified a strong correlation be...
    Authors:Lea Bornemann, Marc Schuster, Saskia Schmitz, Charlyn Sobczak, Clara Bessen, Simon F. Merz, Karl-Heinz Jöckel, Thomas Haverkamp, Matthias Gunzer and Joachim R. Göthert
    Citation:BMC Cancer 2020 20:650
    Content type:Research article
     
    Published on: 
  2. Despite recent advances in cancer immunotherapy, the efficacy of these therapies for the treatment of human prostate cancer patients is low due to the complex immune evasion mechanisms (IEMs) of prostate cance...
    Authors:Mayassa J. Bou-Dargham, Linlin Sha, Qing-Xiang Amy Sang and Jinfeng Zhang
    Citation:BMC Cancer 2020 20:572
    Content type:Research article
     
    Published on: 
  3. Glioma is the most common primary brain tumor, occurring due to the carcinogenesis of glial cells in the brain and spinal cord. Many aspects of the mechanism of its tumorigenesis remain unknown. The relationsh...
    Authors:Zehao Cai, Shoubo Yang, Xiaoyan Li, Feng Chen and Wenbin Li
    Citation:BMC Cancer 2020 20:549
    Content type:Research article
     
    Published on: 
  4. Cervical cancer is caused by Human Papilloma viruses (HPV) and is preceded by precursor stages: Cervical Intraepithelial Neoplasia (CIN). CIN is mostly found in women in their reproductive age and treated with...
    Authors:R. L. O. van de Laar, W. Hofhuis, R. G. Duijnhoven, S. Polinder, W. J. G. Melchers, F. J. van Kemenade, R. L. M. Bekkers and H. J. Van Beekhuizen
    Citation:BMC Cancer 2020 20:539
    Content type:Study protocol
     
    Published on: 
  5. Numerous studies conducted over the past 30 years have pointed to the presence of Epstein–Barr virus (EBV) in gastric cancer samples. This study was aimed to provide a meta-analytic review of the prevalence of...
    Authors:Ahmad Tavakoli, Seyed Hamidreza Monavari, Farid Solaymani Mohammadi, Seyed Jalal Kiani, Saber Armat and Mohammad Farahmand
    Citation:BMC Cancer 2020 20:493
    Content type:Research article
     
    Published on: 
  6. While combinations of immune checkpoint (ICP) inhibitors and neo-adjuvant chemotherapy (NAC) have begun testing in patients with breast cancer (BC), the effects of chemotherapy on ICP expression in circulating...
    Authors:Robert Wesolowski, Andrew Stiff, Dionisia Quiroga, Christopher McQuinn, Zaibo Li, Hiroaki Nitta, Himanshu Savardekar, Brooke Benner, Bhuvaneswari Ramaswamy, Maryam Lustberg, Rachel M. Layman, Erin Macrae, Mahmoud Kassem, Nicole Williams, Sagar Sardesai, Jeffrey VanDeusen…
    Citation:BMC Cancer 2020 20:445
    Content type:Research article
     
    Published on: 
  7. Colon cancer is one of the most common malignancies and the fourth leading cause of cancer-related mortality in the world. Colibactin, which is synthesized by the pks genomic island of E. coli interfere with the ...
    Authors:Faezah Kosari, Mohammad Taheri, Abbas Moradi, Reza Hakimi Alni and Mohammad Yousef Alikhani
    Citation:BMC Cancer 2020 20:267
    Content type:Research article
     
    Published on: 
  8. Although checkpoint blockades have become widely used, the immunological impact in cancer patients, especially those with oral cavity squamous cell carcinoma (OCSCC), has not been well studied.
    Authors:Ying Xiong, David M. Neskey, Joshua D. Horton, Chrystal M. Paulos, Hannah M. Knochelmann, Kent E. Armeson and M. Rita I. Young
    Citation:BMC Cancer 2020 20:229
    Content type:Research article
     
    Published on: 
  9. Programmed cell death 1 (PD-1) is one of the immune checkpoint molecules that negatively regulate the function of T cells. Although recent studies indicate that PD-1 is also expressed on other immune cells bes...
    Authors:Yusuke Kono, Hiroaki Saito, Wataru Miyauchi, Shota Shimizu, Yuki Murakami, Yuji Shishido, Kozo Miyatani, Tomoyuki Matsunaga, Yoji Fukumoto, Yuji Nakayama, Chiye Sakurai, Kiyotaka Hatsuzawa and Yoshiyuki Fujiwara
    Citation:BMC Cancer 2020 20:175
    Content type:Research article
     
    Published on: 
  10. Alterations in peripheral blood lymphocytes in cervical cancer have been reported, although conflicting views exist. The present study investigated the distributions of lymphocyte subsets in tumor tissue and p...
    Authors:Yutuan Wu, Shuang Ye, Shyamal Goswami, Xuan Pei, Libing Xiang, Xiaoming Zhang and Huijuan Yang
    Citation:BMC Cancer 2020 20:173
    Content type:Research article
     
    Published on: 
  11. The epidermal growth factor receptor (EGFR) is pivotal for growth of epithelial cells and is overexpressed in several epithelial cancers like head and neck squamous cell carcinoma (HNSCC). EGFR signalling is a...
    Authors:Anas H. A. Abu-Humaidan, Lars Ekblad, Johan Wennerberg and Ole E. Sørensen
    Citation:BMC Cancer 2020 20:121
    Content type:Research article
     
    Published on: 
  12. Colorectal cancer (CRC) is a major killer. Host immunity is important in tumorigenesis. Direct comparison among IL-36α, IL-36β and IL-36γ in the prognosis of CRC is unclear.
    Authors:Feier Chen, Meng Qu, Feng Zhang, Zhenyu Tan, Qinghua Xia, Brett D. Hambly, Shisan Bao and Kun Tao
    Citation:BMC Cancer 2020 20:92
    Content type:Research article
     
    Published on: 
  13. There are many types of therapies for cancer. In these days, immunotherapies, especially immune checkpoint inhibitors, are focused on. Though many types of immune checkpoint inhibitors are there, the differenc...
    Authors:Kazushige Yoshida, Masanori Okamoto, Jun Sasaki, Chika Kuroda, Haruka Ishida, Katsuya Ueda, Hirokazu Ideta, Takayuki Kamanaka, Atsushi Sobajima, Takashi Takizawa, Manabu Tanaka, Kaoru Aoki, Takeshi Uemura, Hiroyuki Kato, Hisao Haniu and Naoto Saito
    Citation:BMC Cancer 2020 20:25
    Content type:Research article
     
    Published on: 
  14. Patients with lymphoma are at risk for developing pulmonary opportunistic infections due to immunocompromise. However, clinical reports of concurrent lymphoma and opportunistic infection at presentation are ra...
    Authors:Lianyou Shao, Longxiang Jiang, Siyao Wu, Lihua Yu, Liangxing Wang and Xiaoying Huang
    Citation:BMC Cancer 2020 20:15
    Content type:Case report
     
    Published on: 
  15. Glioblastomas (GBM) are therapy-resistant tumors with a profoundly immunosuppressive tumor microenvironment. Chemotherapy has shown limited efficacy against GBM. Systemic delivery of chemotherapeutic drugs is ...
    Authors:Julio Enríquez Pérez, Jan Kopecky, Edward Visse, Anna Darabi and Peter Siesjö
    Citation:BMC Cancer 2020 20:7
    Content type:Research article
     
    Published on: 
  16. Myeloma cells retain B cell functions, considered to be potential antigen presenting cells, yet there is little information regarding promoting Th2 cell proliferation or the direct effects to myeloma on the Th...
    Authors:Faqing Tian, Bo Lu, Ziren Chen, Junru Liu, Delan Ji, Juheng Li, Meiqin Tang, Wei Zhu and Juan Li
    Citation:BMC Cancer 2019 19:1246
    Content type:Research article
     
    Published on: 
  17. Immune checkpoint inhibitors (ICIs) have achieved unprecedented success in cancer treatment over the past decade. The application of ICIs hasled to the discovery of various types of immune-related adverse even...
    Authors:Yuan Liu, Zhi Liu, Xuejun Zeng, Chunmei Bai, Lin Chen, Songbai Lin and Xinlun Tian
    Citation:BMC Cancer 2019 19:1193
    Content type:Case report
     
    Published on: 
  18. In pediatric sarcomas, outcomes of established therapies still remain poor, especially due to high-grade resistances to chemotherapeutic compounds. Taking novel biological approaches into account, virotherapy ...
    Authors:Chihab Klose, Susanne Berchtold, Marina Schmidt, Julia Beil, Irina Smirnow, Sascha Venturelli, Markus Burkard, Rupert Handgretinger and Ulrich M. Lauer
    Citation:BMC Cancer 2019 19:1172
    Content type:Research article
     
    Published on: 
  19. This study aimed to assess the effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing treatment with immune checkpoint inhibitors (ICIs).
    Authors:Hyunho Kim, Ji Eun Lee, Sook Hee Hong, Myung Ah. Lee, Jin Hyoung Kang and In-Ho Kim
    Citation:BMC Cancer 2019 19:1100
    Content type:Research article
     
    Published on: 
  20. NY-BR-1 has been described as a breast cancer associated differentiation antigen with intrinsic immunogenicity giving rise to endogenous T and B cell responses. The current study presents the first murine tumo...
    Authors:Krishna Das, David Eisel, Mathias Vormehr, Karin Müller-Decker, Adriane Hommertgen, Dirk Jäger, Inka Zörnig, Markus Feuerer, Annette Kopp-Schneider, Wolfram Osen and Stefan B. Eichmüller
    Citation:BMC Cancer 2019 19:914
    Content type:Research article
     
    Published on: 
  21. Bispecific T-cell engaging antibodies (BiTES), comprising dual anti-CD3 and anti-tumor antigen scFv fragments, are important therapeutic agents for the treatment of cancer. The dual scFv construct for BiTES re...
    Authors:Maciej Kujawski, Lin Li, Supriyo Bhattacharya, Patty Wong, Wen-Hui Lee, Lindsay Williams, Harry Li, Junie Chea, Kofi Poku, Nicole Bowles, Nagarajan Vaidehi, Paul Yazaki and John E. Shively
    Citation:BMC Cancer 2019 19:882
    Content type:Technical advance
     
    Published on: 
  22. Helicobacter pylori (H. pylori) is thought to have an oncogenic effect on the development of gastric malignancies. However, the effect of H. pylori status on the prognosis of gastric diffuse large B-cell lymphoma...
    Authors:Yuan Cheng, Yinan Xiao, Ruofan Zhou, Yi Liao, Jing Zhou and Xuelei Ma
    Citation:BMC Cancer 2019 19:842
    Content type:Research article
     
    Published on: 
  23. To develop a new 18 high-risk human papillomavirus (HR HPV) detection and genotyping assay, which is important to evaluate the risk degree of HR HPV for causing cancers.
    Authors:Xushan Cai, Qinghua Guan, Yu Huan, Ziyu Liu, Jiehua Qi and Shichao Ge
    Citation:BMC Cancer 2019 19:825
    Content type:Research article
     
    Published on: 
  24. Natural killer (NK) cell dysfunction following cancer surgery has been shown to promote metastases. Recent studies demonstrate an emerging role for lipids in the modulation of NK cell innate responses. However...
    Authors:Seyedeh Raheleh Niavarani, Christine Lawson, Orneala Bakos, Marie Boudaud, Cory Batenchuk, Samuel Rouleau and Lee-Hwa Tai
    Citation:BMC Cancer 2019 19:823
    Content type:Research article
     
    Published on: 
  25. There is currently no evidence that hepatitis C virus (HCV) genotype affects survival in patients with hepatocellular carcinoma (HCC). This study aimed to investigate whether the HCV genotype affected the surv...
    Authors:Hye Kyong Park, Sang Soo Lee, Chang Bin Im, Changjo Im, Ra Ri Cha, Wan Soo Kim, Hyun Chin Cho, Jae Min Lee, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung and Ok-Jae Lee
    Citation:BMC Cancer 2019 19:822
    Content type:Research article
     
    Published on: 
  26. Acquired immunodeficiency associated with thymoma is a rare disorder. Here we reported a case of acquired immunodeficiency with thymoma, with an unusual pattern of low CD4+ count with normal gammaglobulin levels.
    Authors:Takahisa Kawamura, Tateaki Naito, Haruki Kobayashi, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Masahiro Endo and Toshiaki Takahashi
    Citation:BMC Cancer 2019 19:762
    Content type:Case report
     
    Published on: 
  27. Hepatitis B virus (HBV) is the leading cause of liver cancer, but the mechanisms by which HBV causes liver cancer are poorly understood and chemotherapeutic strategies to cure liver cancer are not available. A...
    Authors:Joseph Torresi, Bang Manh Tran, Dale Christiansen, Linda Earnest-Silveira, Renate Hilda Marianne Schwab and Elizabeth Vincan
    Citation:BMC Cancer 2019 19:707
    Content type:Review
     
    Published on: 
  28. Immune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating di...
    Authors:Zhi Ji, Zhi Peng, Jifang Gong, Xiaotian Zhang, Jian Li, Ming Lu, Zhihao Lu and Lin Shen
    Citation:BMC Cancer 2019 19:705
    Content type:Research article
     
    Published on: 
  29. In a prospective study with long-term follow-up, we analyzed circulating T cell subsets in patients with metastatic colorectal cancer (mCRC) in the context of primary tumor sidedness, KRAS status, and clinical ou...
    Authors:Beatrix Bencsikova, Eva Budinska, Iveta Selingerova, Katerina Pilatova, Lenka Fedorova, Kristina Greplova, Rudolf Nenutil, Dalibor Valik, Radka Obermannova, Michael A. Sheard and Lenka Zdrazilova-Dubska
    Citation:BMC Cancer 2019 19:687
    Content type:Research article
     
    Published on: 
  30. Nasopharyngeal carcinoma (NPC) is a malignant disease with an enigmatic etiology. NPC associates with Epstein-Barr virus (EBV) and human papillomaviruses (HPVs), while immunological factors also play a role in...
    Authors:Miia Ruuskanen, Ilmo Leivo, Heikki Minn, Tero Vahlberg, Caj Haglund, Jaana Hagström and Heikki Irjala
    Citation:BMC Cancer 2019 19:624
    Content type:Research article
     
    Published on: 
  31. A higher density of tumor-infiltrating lymphocytes (TILs) can lead to greater therapeutic effects and improved prognoses in cancer treatment. Similar results have been observed in breast cancer, particularly i...
    Authors:Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Katsuyuki Takahashi, Hisakazu Fujita, Tsutomu Takashima, Shuhei Tomita, Kosei Hirakawa and Masaichi Ohira
    Citation:BMC Cancer 2019 19:615
    Content type:Research article
     
    Published on: 
  32. Programmed cell death protein-1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have remarkable clinical efficacy in the treatment of non-small cell lung cancer (NSCLC); however, the breakdown of ...
    Authors:Xiaoying Sun, Raheleh Roudi, Ting Dai, Shangya Chen, Bin Fan, Hongjin Li, Yaqiong Zhou, Min Zhou, Bo Zhu, Chengqian Yin, Bin Li and Xin Li
    Citation:BMC Cancer 2019 19:558
    Content type:Research article
     
    Published on: 
  33. Despite considerable efforts at developing therapeutic vaccines for cancer, clinical translation of preclinical successes has been challenging, largely due to the difficulty of inducing strong and sustained cy...
    Authors:Sean K. Maynard, Jason D. Marshall, Randall S. MacGill, Li Yu, Jennifer A. Cann, Lily I. Cheng, Michael P. McCarthy, Corinne Cayatte and Scott H. Robbins
    Citation:BMC Cancer 2019 19:540
    Content type:Research article
     
    Published on: 
  34. Avelumab is an anti-programmed cell death ligand 1 (PD-L1) antibody approved for treatment of Merkel cell carcinoma (MCC) and locally advanced or metastatic urothelial carcinoma. It shares a similar side effec...
    Authors:Michael A. Cardis, Hong Jiang, Julius Strauss, James L. Gulley and Isaac Brownell
    Citation:BMC Cancer 2019 19:539
    Content type:Case report
     
    Published on: 
  35. Metastases account for 90% of all cancer-related deaths, becoming a therapeutic problem. Approximately 50% of all uveal melanoma (UM) patients will develop metastases, mainly in the liver. Post-mortem analyses of...
    Authors:Nyasia M. Jones, Hua Yang, Qing Zhang, Vanessa M. Morales-Tirado and Hans E. Grossniklaus
    Citation:BMC Cancer 2019 19:484
    Content type:Research article
     
    Published on: 
  36. Autoantibodies function as markers of tumorigenesis and have been proposed to enhance early detection of malignancies. We recently reported, using immunoscreening of a T7 complementary DNA (cDNA) library of br...
    Authors:Siddhesh Aras, Marie-Claire Maroun, Yeohan Song, Sudeshna Bandyopadhyay, Azadeh Stark, Zeng-Quan Yang, Michael P. Long, Lawrence I. Grossman and Félix Fernández-Madrid
    Citation:BMC Cancer 2019 19:411
    Content type:Research article
     
    Published on: 
  37. A causal association has been suggested between certain bacteria and colorectal cancer (CRC). Only a few studies have, however, investigated the presence of these bacteria directly in colon tissue with conflic...
    Authors:Caspar Bundgaard-Nielsen, Ulrik T. Baandrup, Lars P. Nielsen and Suzette Sørensen
    Citation:BMC Cancer 2019 19:399
    Content type:Research article
     
    Published on: 
  38. Micafungin is a well-tolerated and effective prophylactic antifungal agent used in hematologic diseases. In this prospective trial, we evaluated the efficacy and safety of prophylactic micafungin during first ...
    Authors:Hyunkyung Park, Jeonghwan Youk, Dong-Yeop Shin, Junshik Hong, Inho Kim, Nam Joong Kim, Jeong-Ok Lee, Soo-Mee Bang, Sung-Soo Yoon, Wan Beom Park and Youngil Koh
    Citation:BMC Cancer 2019 19:358
    Content type:Research article
     
    Published on: 
  39. Different strains of Newcastle disease virus (NDV) worldwide proved to have tumouricidal activity in several types of cancer cells. However, the possible anti-cancer activity of Malaysian NDV AF2240 strain and...
    Authors:Juraimi Raihan, Umar Ahmad, Yoke Keong Yong, Zolkapli Eshak, Fauziah Othman and Aini Ideris
    Citation:BMC Cancer 2019 19:315
    Content type:Research article
     
    Published on: 
    The Correction to this article has been published in BMC Cancer 2019 19:378
  40. Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. Given the success of CAR-T cells directed against ...
    Authors:Natalie S. Grover and Barbara Savoldo
    Citation:BMC Cancer 2019 19:203
    Content type:Review
     
    Published on: 
  41. The clinical and experimental evidences for complement-cancer relationships are solid, whereas an epidemiological study reporting the imbalance of complement system in patients is still lacking.
    Authors:Ping Zhao, Jun Wu, Feiteng Lu, Xuan Peng, Chenlin Liu, Nanjin Zhou and Muying Ying
    Citation:BMC Cancer 2019 19:201
    Content type:Research article
     
    Published on: 
    The Correction to this article has been published in BMC Cancer 2019 19:269
  42. Despite the recent progress in the development of anti-cancer drugs, the treatment of metastatic tumors is usually ineffective. The systemic inflammatory response performs key roles in different stages of the ...
    Authors:O. Abu-Shawer, M. Abu-Shawer, N. Hirmas, A. Alhouri, A. Massad, B. Alsibai, H. Sultan, H. Hammo, M. Souleiman, Y. Shebli and M. Al-Hussaini
    Citation:BMC Cancer 2019 19:141
    Content type:Research article
     
    Published on: 
  43. Human papillomavirus (HPV) is an etiological agent of cervical cancer. Yet co-factors are believed to be involved in HPV-mediated carcinogenesis. Polycyclic aromatic hydrocarbons (PAHs) are considered as one o...
    Authors:Chuqing Zhang, Yunjing Luo, Rugang Zhong, Priscilla T. Y. Law, Siaw Shi Boon, Zigui Chen, Chi-Hang Wong and Paul K. S. Chan
    Citation:BMC Cancer 2019 19:138
    Content type:Research article
     
    Published on: 
  44. Insulin-like Growth Factor Receptor-1 (IGF1R) system sustains the genesis of rhabdomyosarcoma through IGF2 autocrine overexpression. While several IGF1R-targeted strategies have been investigated to interphere...
    Authors:Carla De Giovanni, Patrizia Nanni, Lorena Landuzzi, Marianna L. Ianzano, Giordano Nicoletti, Stefania Croci, Arianna Palladini and Pier-Luigi Lollini
    Citation:BMC Cancer 2019 19:126
    Content type:Research article
     
    Published on: 
  45. Age-related genetic changes in lymphocyte subsets are not currently well documented. BACH2 is a transcription factor that plays an important role in immune-mediated homeostasis by tightly regulating PRDM1 expr...
    Authors:Vu Luan Dang Chi, Soizic Garaud, Pushpamali De Silva, Vincent Thibaud, Basile Stamatopoulos, Mimoune Berehad, Chunyan Gu-Trantien, Mohammad Krayem, Hugues Duvillier, Jean-Nicolas Lodewyckx, Karen Willard-Gallo, Catherine Sibille and Dominique Bron
    Citation:BMC Cancer 2019 19:81
    Content type:Research article
     
    Published on: 

No hay comentarios:

Publicar un comentario